Sigumir

An orally dosed polypeptide complex extracted from the cartilage and bone tissue of young animals, part of the natural branch of the Khavinson bioregulator line, studied almost entirely in Russian-language cell, animal, and uncontrolled clinical work.

Also referenced as: Sigumir A-4, A-4 Sigumir, Sigumir Lingual

Also appears in: Longevity · Longevity

What is Sigumir?

Sigumir is not a single peptide with a sequence. It is a polypeptide complex extracted from animal tissue — described in the peer-reviewed literature only as “a polypeptide complex of cartilage and bone tissues of young animals” (Myakisheva et al., Advances in Gerontology, 2023) — sold in oral capsules under a trade name and the catalog code A-4. It belongs to the natural-extract branch of the bioregulator line developed at the Saint Petersburg Institute of Bioregulation and Gerontology, the same program that produced the synthetic short peptides sold as Cartalax, Epitalon, and Pinealon.

That distinction matters for reading anything written about it. A synthetic tripeptide has a defined structure, a molecular weight, and an analytical target; a tissue extract is a mixture whose composition has never been published. A related cartilage-and-bone preparation from the same program, Chondrolux, is described as “based on an extract from calf cartilage and bone tissue” (Kurilov and Ryzhak, Bulletin of Experimental Biology and Medicine, 2009, 148(6):915–919) — the closest the indexed literature comes to naming a starting material for this class.

It appears in the research-compound market because it is the cartilage-and-bone entry in a widely distributed catalog of organ-specific capsules, because the joint and connective-tissue framing tracks a large consumer interest, and because it is easy to bundle with the other bioregulators sold alongside it.

How it works

The mechanism claims below come from cell and tissue work published by the group that developed the preparation. They describe a cartilage extract or its synthetic analog in culture, not the capsule after swallowing — and in two of the three cases the tested article is a related cartilage preparation rather than Sigumir itself.

• Tissue-selective stimulation of matching cell cultures — polypeptides extracted from calf tissues stimulated growth of the corresponding organotypic cultures from young and old rats, with increased PCNA and decreased p53 expression in the matching tissue. Across a tested range of 0.01–100 ng/mL, the selective effect appeared at 20–50 ng/mL (Ryzhak et al., Advances in Gerontology, 2015, 28(1):97–103). The cartilage arm of that study is named as Chondrolux, not Sigumir; the result belongs to the class, not to this product. Tissue selectivity in this model is the core claim of the whole bioregulator program.
• Regulation of the chondrocyte senescence-associated secretory phenotype — a narrative review reports that chondrocyte SASP is characterized by decreased sirtuin synthesis, impaired extracellular-matrix remodeling, and activated cytokine production, and that Sigumir and the AED tripeptide (Kartalax) regulate the synthesis of the proapoptotic and proliferotropic molecules forming that phenotype (Myakisheva et al., Advances in Gerontology, 2023, 36(3):313–323). This is a review’s summary of the field rather than primary data, and the indexed record does not itemize which individual markers moved.
• Chondrogenic differentiation markers in aging stem cells — in human mesenchymal stem cells undergoing replicative aging, a cartilage polypeptide complex activated gene expression and protein synthesis of SOX9, aggrecan, type II collagen, and COMP at 2,000 ng/mL, an effect the AED tripeptide produced at 200 ng/mL (Myakisheva et al., Advances in Gerontology, 2023, 36(3):383–390). The ten-fold difference in the concentration required is the clearest published contrast between an extract and its synthetic counterpart. Note that the paper names its test article only as “the cartilage polypeptide complex (CPC)” and never as Sigumir.
• The gene-expression model the program rests on — the proposed mechanism is that ultrashort peptides of 2–7 residues penetrate the nucleus and regulate gene expression through interaction with promoter sequences, histones, and DNA (Khavinson et al., Molecules, 2021, 26(22):7053), and the transport work supporting it describes carriage of di- and tripeptides by POT-family transporters such as PEPT1 and PEPT2 and by LAT carriers (Khavinson et al., International Journal of Molecular Sciences, 2022, 23(14):7733). Neither line of work establishes which fragments, if any, survive digestion of a swallowed polypeptide mixture and reach cartilage intact — no absorption or pharmacokinetic study of this preparation has been published.

Research status

There are no registered clinical trials. As of August 2026, a ClinicalTrials.gov search returns no studies for Sigumir, none for Kartalax, and none for peptide bioregulators as an intervention class; a search for “Cartalax” returns a single unrelated enteral-nutrition study matched on fuzzy text, not a bioregulator trial.

PubMed carries Sigumir as a supplementary concept, and the name appears in exactly three indexed records: two reviews and one clinical observation. None is a controlled trial. The frequently cited stem-cell and organotypic-culture papers are not among them — they test cartilage preparations under other designations.

Human data. The only compound-specific human report is an open follow-up of 62 patients in older age groups with temporomandibular joint disease of varied etiology, in which Sigumir was one element of a treatment package that also included rational tooth prosthetics and functional and pharmacological therapy, including therapy for accompanying conditions (Iordanishvili et al., Advances in Gerontology, 2012, 25(1):181–186). The authors report faster resolution of pain, greater mouth opening amplitude, improved chewing function, shorter treatment times, and fewer relapses. With no control group, no randomization, no blinding, and several simultaneous interventions, that design cannot separate the contribution of the capsule from the rest of the package.

Animal data. In an experimental osteoporosis model, two peptide bioregulators — a preparation based on cartilaginous tissue extract and a substance designated T-31 — were both osteoprotective in ovariectomized rats, preventing the fall in bone mineral density after ovariectomy and increasing density that ovariectomy had already reduced, with the cartilage extract preparation significantly the more effective of the two (Povorozniuk, Khavinson, Makogonchuk, Ryzhak et al., Advances in Gerontology, 2007, 20(2):134–137). The paper names the substance as a cartilaginous tissue extract rather than by trade name. Separately, topical Chondrolux — the calf cartilage and bone extract preparation described above — accelerated excision wound healing in old rabbits, with active granulation tissue by day 14 versus days 21–28 in controls (Kurilov and Ryzhak, Bulletin of Experimental Biology and Medicine, 2009, 148(6):915–919).

Review-level claims. A 2023 review from the originating group states that Sigumir and the AED tripeptide have shown high efficacy both in animal models of osteoarthritis and in oral use in older patients with osteoarthritis (Myakisheva et al., Advances in Gerontology, 2023, 36(3):313–323). The osteoarthritis patient studies behind the second half of that statement are not indexed in English, and no controlled trial supporting it appears in PubMed or in any trial registry. A 2020 review of bioregulatory therapy in dentistry likewise discusses cartilage-derived bioregulators — naming sigumir and chondrolux — alongside peptide thymomimetics such as thymalin and cortexin in older patients (Pinelis et al., Advances in Gerontology, 2020, 33(1):137–152).

The joint and cartilage claims attached to this product therefore rest on the general bioregulator literature — organotypic cultures, chondrocyte and stem cell experiments, rodent models, several of them run on related preparations rather than on Sigumir — plus a single uncontrolled clinical observation. No randomized, placebo-controlled trial of Sigumir has been published, no independent group has replicated the work, and no human pharmacokinetic data exists.

Common dosage forms

• Hard oral capsules, commonly containing about 10 mg of the peptide complex, sold in 20- and 60-count packs presented as fixed-length courses of roughly a month.
• A sublingual variant, marketed under a “lingual” designation, which places the same complex under the tongue rather than in the stomach.
• Multi-product bundles pairing the cartilage-and-bone capsules with other organ-specific bioregulator capsules from the same catalog.
• No injectable presentation is marketed under this name. Lyophilized vials in this corner of the market hold the synthetic AED tripeptide, not the extract. The only non-oral route in the literature is topical application of a related cartilage extract preparation in animal wound studies.

This section describes formats only and is not dosing guidance.

Key considerations

• There is no analytical target. Purity and identity testing as practiced for synthetic peptides — HPLC purity against a single main peak, mass spectrometry confirming a molecular weight that matches a stated sequence — has nothing to verify here, because no sequence, composition, or characterization of the complex has been published. A certificate of analysis for a tissue extract can speak to contaminants and gross protein content, not to whether the material is what the label says.
• Animal-sourced material with undocumented provenance. The starting material is livestock tissue. The peer-reviewed record specifies only “young animals,” with a related preparation described as calf-derived, and it contains no sourcing, traceability, or pathogen-inactivation detail; vendor copy about the age of the source animals has no published counterpart. US rules define prohibited cattle materials and bar them from human food, dietary supplements, and cosmetics, with the restrictions keyed to animal age — specified risk materials from cattle 30 months and older — as well as inspection status and specific tissues (FDA final rule, Use of Materials Derived From Cattle in Human Food and Cosmetics, 81 FR 14718, published March 18, 2016). Nothing in the peer-reviewed literature documents how imported capsules of this type are sourced against that framework.
• No approved status anywhere it is sold. Sigumir is not FDA approved for any indication, and it is not a registered medicine in its country of origin either — it is marketed there as a dietary supplement, which is why the literature describes courses of capsules rather than an approved label. An animal-tissue extract without a history of use in the US food supply would fall under the new dietary ingredient rules, which require a premarket safety notification before a supplement containing it enters interstate commerce.
• The evidence traces back to one group. V. Kh. Khavinson and G. A. Ryzhak, the developers of the preparation, appear as authors on essentially every primary study cited above, and the two 2023 papers list the Saint Petersburg Institute of Bioregulation and Gerontology among their affiliations. The one cited paper without either author is a narrative review that summarizes the same body of work rather than testing it independently. That is not disqualifying on its own, but combined with Russian-language publication concentrated in a single journal and the absence of any placebo-controlled trial, it means the evidence has never been stress-tested by an unaffiliated group.
• Easily confused with Cartalax — and with Chondrolux. Cartalax, transliterated Kartalax in several papers, is the synthetic tripeptide Ala-Glu-Asp (AED) and has its own profile; Sigumir is the natural extract. They are studied side by side, marketed together, and described with the same “cartilage bioregulator” language, but they are different substances with different potencies in the same assays. Chondrolux is a third name to keep separate: it is another cartilage-and-bone polypeptide preparation from the same program, listed alongside sigumir as a distinct product in the dentistry review above, and it — not Sigumir — is the test article in the organotypic-culture and rabbit wound studies. Whether the two formulations are identical has never been published, so animal and culture results obtained with Chondrolux should not be read as results for Sigumir capsules. Finally, A-4 is the manufacturer’s catalog code for the cartilage entry in its A-numbered bioregulator line, reused by every reseller that stocks it; it carries no chemical meaning and returns unrelated results in literature searches.